| In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells (NCT00731705) | Indiana University | 2007-01-01 |
| Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation (NCT00369226) | Dana-Farber Cancer Institute | 2006-08-01 |
| Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies (NCT00642031) | Prescient Therapeutics, Ltd. | 2006-08-01 |
| A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies (NCT00402714) | Yale University | 2006-07-01 |
| Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation (NCT00355407) | Dana-Farber Cancer Institute | 2006-06-01 |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies (NCT00405743) | Clavis Pharma | 2006-05-01 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative (NCT00429143) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2006-01-01 |
| Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation (NCT00189488) | Swedish Orphan Biovitrum | 2005-12-01 |
| Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor (NCT00993486) | Kiadis Pharma | 2005-01-01 |
| Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies (NCT00741455) | Dartmouth-Hitchcock Medical Center | 2004-06-01 |
| Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) (NCT00086125) | Merck Sharp & Dohme LLC | 2004-06-01 |
| G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome (NCT00228813) | Emory University | 2004-04-01 |
| Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation (NCT00429416) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2004-03-01 |
| Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies (NCT00202917) | University Hospital Tuebingen | 2004-02-01 |
| Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies (NCT00079391) | National Heart, Lung, and Blood Institute (NHLBI) | 2004-01-01 |
| Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies (NCT00113048) | Genzyme, a Sanofi Company | 2003-12-01 |
| Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells (NCT00770523) | Cooperative Study Group A for Hematology | 2003-12-01 |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support (NCT00506857) | M.D. Anderson Cancer Center | 2003-11-01 |
| Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation (NCT00138112) | Memorial Sloan Kettering Cancer Center | 2003-11-01 |
| Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) (NCT00231309) | Emory University | 2003-07-01 |
| Infusional C-myb ASODN in Advanced Hematologic Malignancies (NCT00780052) | Abramson Cancer Center at Penn Medicine | 2002-09-01 |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation (NCT00144703) | Dana-Farber Cancer Institute | 2002-07-01 |
| Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation (NCT00146614) | Dana-Farber Cancer Institute | 2002-07-01 |
| Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) (NCT00693927) | University of Liege | 2002-03-01 |
| Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies (NCT00061620) | M.D. Anderson Cancer Center | 2001-09-06 |
| Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies (NCT00208923) | Emory University | 1998-07-01 |
| IUdR/BUdR Cell Cycle Labelling (NCT00042250) | M.D. Anderson Cancer Center | 1992-05-01 |
| Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants (NCT01881334) | Joanne Kurtzberg, MD | |
| Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies (NCT07346105) | Orca Biosystems, Inc. | |